Why Choose Private Prescription for Weight Management?
Private vs NHS Routes for Wegovy and Mounjaro Alternatives
The NHS pathway for accessing Wegovy or Mounjaro alternatives involves multiple gatekeeping stages that can delay treatment for months. Patients must first secure a GP referral to specialist weight management services, meet strict BMI criteria (often BMI ≥35 with comorbidities), then join waiting lists averaging 6-8 months in most UK regions. Private prescription eliminates these barriers whilst providing access to identical medications—genuine Novo Nordisk Wegovy and Eli Lilly Mounjaro, not generic alternatives.
EverydayMeds' private prescription service transforms this process into a streamlined 48-72 hour journey from assessment to delivery. Our clinical team, operating under GPhC registration #9012878, reviews applications against the same MHRA-approved criteria used by NHS services, ensuring clinical safety whilst removing administrative delays. This approach proves particularly valuable for patients whose BMI falls just outside NHS thresholds or who cannot access specialist services due to geographical limitations.
Transparent Pricing for Wegovy and Mounjaro Alternatives
Private prescription costs remain transparent at EverydayMeds, with Wegovy starting at £79.99 for the 0.25mg starter dose (using discount code FIRST40 for new customers). The complete dose escalation journey spans £79.99 (weeks 1-4) through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to the maintenance dose at £209.99 (2.4mg). Our Getting Started bundles, such as the Intro Duo (0.25mg & 0.5mg) at £169.99, provide convenient multi-dose packages for seamless dose progression.
Mounjaro pricing follows a similar structure, with both treatments representing prescription-only medicines requiring clinical oversight. Returning customers benefit from the DOSE25 discount code applied at checkout, whilst our 2-pen and 3-pen bundles offer Reliable Supply continuity. Unlike NHS provision, private prescription allows flexible dose timing and personalised escalation schedules based on individual tolerance and response patterns.
Clinical Evidence Behind Wegovy and Mounjaro Alternatives
Wegovy's clinical foundation rests on the landmark STEP trial programme, with STEP 1 demonstrating approximately 15% average weight reduction at 68 weeks versus 2.4% with placebo, as published by Wilding et al. in the New England Journal of Medicine, 2021. The STEP 2 trial specifically examined patients with type 2 diabetes, showing sustained efficacy in this population. These trials established semaglutide's role as a prescription-only medicine requiring concurrent lifestyle modifications.
Mounjaro's clinical profile emerges from the SURMOUNT studies, establishing tirzepatide's dual GIP/GLP-1 receptor agonism mechanism. Both medications require administration alongside a reduced-calorie diet and increased physical activity, with individual responses varying based on adherence, baseline characteristics, and concurrent health conditions.
Mechanism Differences: GLP-1 vs Dual Receptor Targeting
Wegovy (semaglutide) functions as a selective GLP-1 receptor agonist, mimicking the incretin hormone that signals satiety to brain appetite centres. This mechanism reduces hunger sensations whilst promoting feelings of fullness after smaller meal portions, supporting natural portion control behaviours. Mounjaro (tirzepatide) employs dual receptor targeting, activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) pathways for potentially enhanced metabolic effects. Both treatments work centrally on hypothalamic appetite regulation rather than through peripheral mechanisms like absorption inhibitors. The weekly injection schedule for both medications supports consistent therapeutic levels, reducing the burden of daily medication adherence compared to oral weight management alternatives.
Streamlined Private Prescription Ordering Process
EverydayMeds' private prescription pathway begins with a comprehensive 3-minute online clinical assessment covering medical history, current medications, and weight management goals. Our qualified prescribers review each application within 72 hours (24 hours for express service), ensuring appropriate patient selection for either Wegovy or Mounjaro based on individual clinical profiles. Upon approval, medications ship via next-day cold-chain delivery, maintaining the 2-8°C temperature requirements throughout transit. This process bypasses GP appointment scheduling, specialist referral delays, and geographic limitations affecting NHS service access. Patients receive detailed injection training materials, dose escalation guidance, and ongoing clinical support throughout their treatment journey.
Storage and Practical Considerations for Treatment Success
Both Wegovy and Mounjaro require refrigerated storage at 2-8°C before first use, though Wegovy offers superior travel convenience with 6 weeks of room temperature stability versus Mounjaro's 21-day limit. The FlexTouch pen design used by Wegovy provides pre-filled, single-use injection convenience with dose escalation progressing systematically every four weeks. Mounjaro utilises similar pre-filled pen technology with its own escalation schedule. Proper storage maintains medication potency whilst room temperature allowances support travel and lifestyle flexibility. Both treatments integrate into weekly routines, with many patients choosing consistent injection days (such as Sunday evenings) to establish sustainable habits alongside dietary and exercise modifications.
Private Prescription Advantages for Weight Management Alternatives
Private prescription access removes the postcode lottery affecting NHS specialist weight management services, where availability varies dramatically between Clinical Commissioning Groups. Many NHS services impose additional criteria beyond NICE guidance, such as mandatory 6-month weight loss attempts or psychological assessments that can extend timelines further. Private prescription eliminates these regional variations whilst maintaining clinical safety through qualified prescriber oversight.
The flexibility of private prescription also accommodates individual circumstances that NHS pathways may not address, such as self-employed patients who cannot attend multiple weekday appointments, or those requiring dose timing adjustments for work or travel schedules. This personalised approach proves particularly valuable for patients who have previously engaged with weight management services but require pharmaceutical intervention to maintain long-term success.
Next Steps: Accessing Wegovy or Mounjaro Through Private Prescription
Beginning your weight management journey through EverydayMeds starts with our confidential online assessment at https://everydaymeds.co.uk/collections/wegovy, designed to gather the clinical information our prescribers need for informed treatment decisions. New customers can apply discount code FIRST40 at checkout, whilst returning patients use DOSE25 for ongoing treatment value. Our clinical team operates under strict GPhC standards (#9012878), ensuring every prescription meets MHRA safety requirements for these prescription-only medicines. Both Wegovy and Mounjaro are available through our service—your prescriber can help determine which treatment aligns with your clinical profile and weight management objectives. Remember that sustainable weight management requires commitment to lifestyle changes alongside pharmaceutical intervention, with both medications designed to support rather than replace healthy eating and regular physical activity.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
